Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Azacitidine in MDS
NCT01186939Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Primary endpoint: Treatment Emergent Adverse Events. Started Apr 2007; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01186939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01186939.